CureVac (CVAC) Competitors $5.36 -0.04 (-0.65%) As of 11:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CVAC vs. CRSP, TGTX, ACAD, KRYS, CYTK, MENS, ADMA, PCVX, AAPG, and PTCTShould you be buying CureVac stock or one of its competitors? The main competitors of CureVac include CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), ACADIA Pharmaceuticals (ACAD), Krystal Biotech (KRYS), Cytokinetics (CYTK), Jyong Biotech (MENS), ADMA Biologics (ADMA), Vaxcyte (PCVX), Ascentage Pharma Group International (AAPG), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical products" industry. CureVac vs. Its Competitors CRISPR Therapeutics TG Therapeutics ACADIA Pharmaceuticals Krystal Biotech Cytokinetics Jyong Biotech ADMA Biologics Vaxcyte Ascentage Pharma Group International PTC Therapeutics CureVac (NASDAQ:CVAC) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation. Is CVAC or CRSP more profitable? CureVac has a net margin of 38.21% compared to CRISPR Therapeutics' net margin of -1,229.43%. CureVac's return on equity of 29.57% beat CRISPR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CureVac38.21% 29.57% 25.41% CRISPR Therapeutics -1,229.43%-20.05%-17.09% Do insiders and institutionals have more ownership in CVAC or CRSP? 17.3% of CureVac shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, CVAC or CRSP? CureVac has a beta of 2.53, meaning that its stock price is 153% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Does the media refer more to CVAC or CRSP? In the previous week, CRISPR Therapeutics had 7 more articles in the media than CureVac. MarketBeat recorded 10 mentions for CRISPR Therapeutics and 3 mentions for CureVac. CureVac's average media sentiment score of 0.90 beat CRISPR Therapeutics' score of 0.77 indicating that CureVac is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CureVac 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, CVAC or CRSP? CureVac has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCureVac$579.18M2.07$175.50M$0.965.58CRISPR Therapeutics$37.31M135.98-$366.25M-$5.43-10.27 Do analysts rate CVAC or CRSP? CureVac currently has a consensus target price of $6.83, suggesting a potential upside of 27.61%. CRISPR Therapeutics has a consensus target price of $71.60, suggesting a potential upside of 28.36%. Given CRISPR Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CRISPR Therapeutics is more favorable than CureVac.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20CRISPR Therapeutics 1 Sell rating(s) 7 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.47 SummaryCureVac beats CRISPR Therapeutics on 9 of the 16 factors compared between the two stocks. Get CureVac News Delivered to You Automatically Sign up to receive the latest news and ratings for CVAC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CVAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVAC vs. The Competition Export to ExcelMetricCureVacMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.20B$3.18B$5.80B$10.16BDividend YieldN/A2.32%5.69%4.61%P/E Ratio5.5821.4874.7325.99Price / Sales2.07301.34470.3491.76Price / Cash6.1645.3337.0859.91Price / Book1.599.6312.256.31Net Income$175.50M-$53.32M$3.28B$270.66M7 Day Performance-0.65%0.95%1.39%3.52%1 Month Performance-2.10%9.68%7.70%6.79%1 Year Performance73.30%13.38%64.01%28.29% CureVac Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVACCureVac3.9367 of 5 stars$5.36-0.6%$6.83+27.6%+77.9%$1.20B$579.18M5.58880Short Interest ↑CRSPCRISPR Therapeutics3.3247 of 5 stars$51.83-2.3%$71.60+38.1%+23.0%$4.71B$37.31M-9.55460TGTXTG Therapeutics4.1683 of 5 stars$29.33+1.3%$46.25+57.7%+40.7%$4.65B$329M79.27290Positive NewsACADACADIA Pharmaceuticals4.3958 of 5 stars$25.99-0.9%$28.88+11.1%+51.7%$4.38B$957.80M19.54510Positive NewsAnalyst ForecastKRYSKrystal Biotech4.942 of 5 stars$147.70-2.0%$210.38+42.4%-27.4%$4.27B$290.52M30.02210Positive NewsCYTKCytokinetics4.3293 of 5 stars$35.33-5.4%$71.58+102.6%-0.8%$4.23B$18.47M-6.93250Insider TradeMENSJyong BiotechN/A$54.81-1.3%N/AN/A$4.17BN/A0.0031News CoverageGap DownADMAADMA Biologics3.7357 of 5 stars$17.26-0.7%$27.67+60.3%-4.7%$4.12B$426.45M20.07530Positive NewsPCVXVaxcyte2.2918 of 5 stars$30.79+0.1%$136.50+343.3%-70.9%$4.00BN/A0.00160Positive NewsAnalyst ForecastAAPGAscentage Pharma Group InternationalN/A$42.47+3.3%N/AN/A$3.95B$134.35M0.00600Positive NewsPTCTPTC Therapeutics3.6468 of 5 stars$49.33-0.9%$69.15+40.2%+88.9%$3.92B$806.78M7.081,410Insider Trade Related Companies and Tools Related Companies CRSP Competitors TGTX Competitors ACAD Competitors KRYS Competitors CYTK Competitors MENS Competitors ADMA Competitors PCVX Competitors AAPG Competitors PTCT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CVAC) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredNVDA: The cracks are beginning to showThe media hasn't caught up to the story yet, but when they do, this stock could leave Nvidia in the dust. I...InvestorPlace | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredUrgent: $3,452.50 a Month in Passive "AI Equity Checks"The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share CureVac With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CVAC Stock Alerts